Hypnosedation for endocavitary uterovaginal applications: A pilot study.


Journal

Brachytherapy
ISSN: 1873-1449
Titre abrégé: Brachytherapy
Pays: United States
ID NLM: 101137600

Informations de publication

Date de publication:
Historique:
received: 27 12 2019
revised: 18 03 2020
accepted: 25 03 2020
pubmed: 4 5 2020
medline: 14 4 2021
entrez: 4 5 2020
Statut: ppublish

Résumé

Implantations for uterovaginal brachytherapy are usually performed under general or spinal anesthesia, which are not without risk. As it is a rather short procedure and since postoperative pain is minimal, hypnosedation was proposed to selected patients requiring endocavitary applications as part of their routine treatment. Consecutive patients requiring intracavitary uterovaginal brachytherapy from January to October 2019 were included if they accepted the procedure. A premedication was systematically administered. Hypnosedation was based on an Ericksonian technique. The procedure was immediately interrupted if the patient requested it, in cases of extreme anxiety or pain. Procedure was in that case rescheduled with a "classical" anesthesia technique. A total of 20 patients were included. Four patients had to be converted toward a general anesthesia: one because of a fibroma on the probe's way and three young patients with a very anteverted/retroverted uterus that was painful at every mobilization. Mean and maximum pain scores during implant were 2.9/10 and 5.1/10, respectively. The most painful maneuver was cervical dilation for 45% of the patients, followed by mold insertion in 40% of cases. About 85% of the patients declared that hypnosis helped them relax; 90% of the patients would recommend the technique. No procedure-related complication occurred. With a 70% success rate (correct implant with mean pain and anxiety scores < 5), one can conclude that uterovaginal brachytherapy implantation under hypnosedation is feasible and received a high satisfaction rate from the patients. This technique may reduce overall treatment time in a context of difficult access to the OR and to anesthesiologists, while reducing anesthetic drugs resort and postoperative nausea.

Identifiants

pubmed: 32359938
pii: S1538-4721(20)30053-2
doi: 10.1016/j.brachy.2020.03.008
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

462-469

Informations de copyright

Copyright © 2020 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Manon Kissel (M)

Radiation Oncology Department, Brachytherapy Unit, Gustave Roussy, Villejuif, France. Electronic address: manonkissel@hotmail.com.

Mickaël Andraud (M)

Radiation Oncology Department, Brachytherapy Unit, Gustave Roussy, Villejuif, France.

Anne-Sophie Duhamel (AS)

Radiation Oncology Department, Brachytherapy Unit, Gustave Roussy, Villejuif, France.

Geoffroy Boulle (G)

Radiation Oncology Department, Brachytherapy Unit, Gustave Roussy, Villejuif, France.

Edouard Romano (E)

Radiation Oncology Department, Brachytherapy Unit, Gustave Roussy, Villejuif, France.

Samir Achkar (S)

Radiation Oncology Department, Brachytherapy Unit, Gustave Roussy, Villejuif, France.

Rémi Bourdais (R)

Radiation Oncology Department, Brachytherapy Unit, Gustave Roussy, Villejuif, France.

Minh-Hanh Ta (MH)

Radiation Oncology Department, Brachytherapy Unit, Gustave Roussy, Villejuif, France.

Arthur Pounou (A)

Radiation Oncology Department, Brachytherapy Unit, Gustave Roussy, Villejuif, France.

Tamizhanban Kumar (T)

Radiation Oncology Department, Brachytherapy Unit, Gustave Roussy, Villejuif, France.

Bernard Celestin (B)

Anesthesiology Department, Villejuif, France.

Lauriane Bordenave (L)

Anesthesiology Department, Villejuif, France.

Valérie Billard (V)

Anesthesiology Department, Villejuif, France.

Christine Haie-Meder (C)

Radiation Oncology Department, Brachytherapy Unit, Gustave Roussy, Villejuif, France.

Cyrus Chargari (C)

Radiation Oncology Department, Brachytherapy Unit, Gustave Roussy, Villejuif, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH